PSMA PET/CT

DIAGNOSTIC_TEST11 trials

Sponsors

Sir Mortimer B. Davis - Jewish General Hospital, Jewish General Hospital, Norwegian University of Science and Technology, University Hospital, Brest, Peter MacCallum Cancer Centre, Australia

Conditions

Adenocarcinoma of the ProstateBiochemical Recurrence (BCR)CancerHigh Risk Prostate CancerHigh-Risk Localized Prostate CancerIntermediate Risk Prostate CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Phase 1

RYZ711 Diagnostic Platform Study

Not yet recruitingNCT07862582

RayzeBio, Inc.Adenocarcinoma of the Prostate, Biochemical Recurrence (BCR), High-Risk Localized Prostate Cancer +3

Start: 2026-10-01End: 2027-12-01Target: 116Updated: 2026-10-26

Phase 2

SUV on PSMA PET/CT in Non-Prostate Tumors

TerminatedNCT03841760

Sir Mortimer B. Davis - Jewish General HospitalCancer

Start: 2019-07-25End: 2023-04-01Updated: 2023-04-12

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

RecruitingNCT07393867

Martin T. King, MD, PhDHigh Risk Prostate Cancer, Intermediate Risk Prostate Cancer, Prostate Cancer

Start: 2026-04-29End: 2027-12-15Target: 23Updated: 2026-05-29

Phase 3

PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI

Active, not recruitingNCT05154162

Peter MacCallum Cancer Centre, AustraliaProstate Cancer

Start: 2022-03-02End: 2027-08-01Target: 660Updated: 2026-03-03

Unknown Phase

PILOT Quality check of PSMA PET for imaging salivary gland toxicity

Active, not recruitingNL-OMON42838

Antoni van Leeuwenhoek ZiekenhuisToxiciteit in speekselklieren van uitwendige bestraling Salivary gland toxicity Xerostomia

Start: 2016-08-01Target: 5Updated: 2024-02-28

Upregulation of PSMA Receptors After Androgen Deprivation Therapy on PSMA PET/CT Imaging in Prostate Cancer

CompletedNCT03938766

Jewish General HospitalProstate Cancer

Start: 2018-02-02End: 2020-02-01Updated: 2020-02-12

Determining the dose-effect relation of salivary gland irradiation and functional cell loss with PSMA PET

Active, not recruitingNL-OMON49750

Antoni van Leeuwenhoek Ziekenhuisdry mouth (after radiotherapy) Xerostomia

Start: 2017-11-21Target: 30Updated: 2024-02-28

PSMA-PET and MRI for Detection of Recurrent Prostate Cancer After Radical Treatment

CompletedNCT04298112

Norwegian University of Science and TechnologyProstatic Neoplasms

Start: 2020-05-01End: 2023-05-01Updated: 2024-11-15

Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).

TerminatedNCT04745871

University Hospital, BrestProstate Cancer

Start: 2021-05-20End: 2025-11-21Updated: 2026-06-11

Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient

RecruitingNCT06209853

Assiut UniversityProstatic Neoplasms

Start: 2024-01-20End: 2025-04-01Target: 59Updated: 2024-07-15

Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer

Not yet recruitingNCT06387238

Peking University First HospitalProstate Adenocarcinoma

Start: 2024-05-01End: 2026-06-30Target: 150Updated: 2024-04-29

Related Papers

Effect of [<sup>68</sup>Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

2026-06-10

Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [<sup>68</sup>Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer.

2023-12-0620 citations

PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer.

Journal of Clinical Oncology2023-02-203 citations